Merck (MRK) announced the CHMP of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, the company's anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. The positive opinion is based on results from the pivotal phase 3 KEYNOTE-564 trial.
The CHMP's recommendation will now be reviewed by the European Commission, and a final decision is anticipated in the first quarter of 2022.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.